Brokerage firm Stifel Nicolaus Maintains its rating on Lexicon Pharmaceuticals(NASDAQ:LXRX). In a research note issued to the investors, the brokerage major Raises the price-target to $26.00 per share. The shares have been rated Buy. The rating by Stifel Nicolaus was issued on Aug 5, 2016.
In a different note, Citigroup said it Initiates Coverage on Lexicon Pharmaceuticals, according to a research note issued on Aug 2, 2016. The shares have been rated ‘Buy’ by the firm.
Lexicon Pharmaceuticals (LXRX) shares turned negative on Wednesdays trading session with the shares closing down -0.12 points or -0.77% at a volume of 5,53,247. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $15.92. The peak price level was also seen at $15.92 while the days lowest was $15.41. Finally the shares closed at $15.53. The 52-week high of the shares is $16.98 while the 52-week low is $7.65. According to the latest information available, the market cap of the company is $1,613 M.
Lexicon Pharmaceuticals(LXRX) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $20.09M. Analysts had an estimated revenue of $12.36M. Earnings per share were $-0.37. Analysts had estimated an EPS of $-0.41.
Several Insider Transactions has been reported to the SEC. On Jun 8, 2016, James F Tessmer (VP, Finance & Accounting) sold 1,500 shares at $15.00 per share price.
Lexicon Pharmaceuticals Inc. (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate is an orally delivered small molecule drug candidate as a treatment for carcinoid syndrome. It has completed two Phase II clinical trials and is conducting a single Phase III clinical trial of telotristat etiprate in carcinoid syndrome patients. The Company’s sotagliflozin is an orally delivered small molecule drug candidate as a treatment for type 1 and type 2 diabetes. The Company has completed two Phase II clinical trials of sotagliflozin in type 2 diabetes patients and an additional clinical trial of sotagliflozin in type 2 diabetes patients with renal impairment. It has also completed a Phase II clinical trial of sotagliflozin in type 1 diabetes patients.